Loading...
506285 logo

Bayer CropScience LimitedBSE:506285 株式レポート

時価総額 ₹207.1b
株価
₹4.61k
₹5.21k
11.5% 割安 内在価値ディスカウント
1Y-0.2%
7D-3.4%
ポートフォリオ価値
​
表示

Bayer CropScience Limited

BSE:506285 株式レポート

時価総額：₹207.1b

Bayer CropScience（506285）株式概要

バイエル クロップサイエンス社は、殺虫剤、殺菌剤、除草剤、その他さまざまな農薬製品、トウモロコシ種子の製造、販売、流通をインド、ドイツ、バングラデシュ、および海外で行っている。 詳細

506285 ファンダメンタル分析
スノーフレーク・スコア
評価0/6
将来の成長2/6
過去の実績6/6
財務の健全性5/6
配当金4/6

報酬

収益は年間10.92%増加すると予測されています

過去1年間で収益は28.7%増加しました

リスク分析

2.71%の配当はフリーキャッシュフローで十分にカバーされていない


506285 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Analyst Price Targets

View all narratives
Materials opportunity
UG logo
Upside Gold
Fair Value from
CA$5.0768.0% 割安 内在価値ディスカウント

An Undervalued 3.3Moz Gold Project in Canada

Key takeaways Upside Gold is developing the Kena Gold Project, near the town of Nelson in the Kootenays region of southern British Columbia. Kena hosts a historical gold resource of 3.33 million ounces (561,000 ounces Indicated and 2.77 million ounces Inferred) across a 10,200-hectare land package.

Read full narrative
Read narrative

Bayer CropScience Limited 競合他社

価格と性能

株価の高値、安値、推移の概要Bayer CropScience
過去の株価
現在の株価₹4,608.85
52週高値₹6,539.95
52週安値₹4,276.85
ベータ0.25
1ヶ月の変化-3.89%
3ヶ月変化2.68%
1年変化-0.19%
3年間の変化11.47%
5年間の変化-14.87%
IPOからの変化6,045.14%

最新ニュース

ナラティブ更新 • May 01

506285: Stable Assumptions And Upcoming Results Will Shape A Balanced Outlook

Analysts have maintained their fair value estimate for Bayer CropScience at ₹5,209.63 per share, making only minor adjustments to assumptions such as discount rate, revenue growth, profit margin and future P/E. This suggests that their overall view on the stock's long-term potential remains broadly unchanged.
ナラティブ更新 • Apr 17

506285: Upcoming Results And Refined Assumptions Will Support A Balanced Outlook

The analyst price target for Bayer CropScience has been adjusted slightly higher to ₹5,209.63 from ₹5,187.13. Analysts point to updated fair value estimates, a modest change in the assumed discount rate, and revised expectations for revenue, profit margins, and future P/E as key inputs behind this move.
ナラティブ更新 • Apr 02

506285: Upcoming Results And Stable Assumptions Will Support A Balanced Outlook

Analysts have kept their price target on Bayer CropScience broadly unchanged around ₹5,187. This reflects only marginal model tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, rather than any shift in their core view.
ナラティブ更新 • Mar 19

506285: Upcoming Results And Stable Assumptions Will Support A Positive Outlook

Analysts have marginally revised their price target for Bayer CropScience to ₹5,187, reflecting small tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E, rather than any major shift in the outlook. What's in the News A board meeting is scheduled for February 11, 2026, to review and consider the unaudited financial results for the quarter ended December 31, 2025 (Key Developments).
ナラティブ更新 • Mar 04

506285: Sustainability Partnership And Upcoming Results Will Support A Positive Outlook

Analysts have kept their price target for Bayer CropScience broadly unchanged around ₹5,187, citing only small tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E that do not materially alter their overall view on the stock. What's in the News Bayer CropScience has scheduled a board meeting on February 11, 2026 to consider the unaudited financial results for the quarter ended December 31, 2025 (company filing).
ナラティブ更新 • Feb 17

506285: Sustainability Collaboration And Upcoming Results Will Support A Balanced Outlook

Analysts have trimmed their price target for Bayer CropScience to ₹5,187 from about ₹5,278, reflecting updated views on slightly lower fair value, a modestly adjusted discount rate, marginally different margin expectations and a revised future P/E assumption, while keeping revenue growth assumptions largely supportive. What's in the News Bayer CropScience has scheduled a board meeting on February 11, 2026 to consider the unaudited financial results for the quarter ended December 31, 2025 (company filing).

Recent updates

ナラティブ更新 • May 01

506285: Stable Assumptions And Upcoming Results Will Shape A Balanced Outlook

Analysts have maintained their fair value estimate for Bayer CropScience at ₹5,209.63 per share, making only minor adjustments to assumptions such as discount rate, revenue growth, profit margin and future P/E. This suggests that their overall view on the stock's long-term potential remains broadly unchanged.
ナラティブ更新 • Apr 17

506285: Upcoming Results And Refined Assumptions Will Support A Balanced Outlook

The analyst price target for Bayer CropScience has been adjusted slightly higher to ₹5,209.63 from ₹5,187.13. Analysts point to updated fair value estimates, a modest change in the assumed discount rate, and revised expectations for revenue, profit margins, and future P/E as key inputs behind this move.
ナラティブ更新 • Apr 02

506285: Upcoming Results And Stable Assumptions Will Support A Balanced Outlook

Analysts have kept their price target on Bayer CropScience broadly unchanged around ₹5,187. This reflects only marginal model tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, rather than any shift in their core view.
ナラティブ更新 • Mar 19

506285: Upcoming Results And Stable Assumptions Will Support A Positive Outlook

Analysts have marginally revised their price target for Bayer CropScience to ₹5,187, reflecting small tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E, rather than any major shift in the outlook. What's in the News A board meeting is scheduled for February 11, 2026, to review and consider the unaudited financial results for the quarter ended December 31, 2025 (Key Developments).
ナラティブ更新 • Mar 04

506285: Sustainability Partnership And Upcoming Results Will Support A Positive Outlook

Analysts have kept their price target for Bayer CropScience broadly unchanged around ₹5,187, citing only small tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E that do not materially alter their overall view on the stock. What's in the News Bayer CropScience has scheduled a board meeting on February 11, 2026 to consider the unaudited financial results for the quarter ended December 31, 2025 (company filing).
ナラティブ更新 • Feb 17

506285: Sustainability Collaboration And Upcoming Results Will Support A Balanced Outlook

Analysts have trimmed their price target for Bayer CropScience to ₹5,187 from about ₹5,278, reflecting updated views on slightly lower fair value, a modestly adjusted discount rate, marginally different margin expectations and a revised future P/E assumption, while keeping revenue growth assumptions largely supportive. What's in the News Bayer CropScience has scheduled a board meeting on February 11, 2026 to consider the unaudited financial results for the quarter ended December 31, 2025 (company filing).
ナラティブ更新 • Feb 03

506285: Expanded Sustainability Partnership Will Support Bullish Outlook Into Next Year

Analysts have kept their fair value estimate for Bayer CropScience effectively unchanged at €5,277.67, with only marginal tweaks to assumptions such as discount rate, revenue growth, profit margin and future P/E. This reflects steady underlying expectations rather than a shift in view.
ナラティブ更新 • Jan 20

506285: Farmer Focused Sustainability Partnership Will Support Bullish Outlook Into Next Year

Analysts have slightly reduced their fair value estimate for Bayer CropScience to about €5,278. This reflects modest tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E, without a major shift in the overall thesis.
ナラティブ更新 • Jan 05

506285: Interim Dividend Decision Will Support Bullish Outlook Into Next Year

Analysts have kept their fair value estimate for Bayer CropScience steady, with only marginal tweaks to the discount rate, revenue growth, profit margin, and future P/E assumptions guiding a largely unchanged price target narrative. What's in the News A board meeting is scheduled for November 7, 2025, to review the unaudited financial results for the quarter ended September 30, 2025.
ナラティブ更新 • Dec 21

506285: Interim Dividend Decision Will Drive Bullish Momentum Into Next Year

Analysts have modestly raised their price target on Bayer CropScience by about €5, citing a slightly higher long term discount rate and valuation assumptions that leave fair value largely unchanged. What's in the News Board meeting scheduled for November 7, 2025, to review unaudited financial results for the quarter ended September 30, 2025 (Key Developments) Board to consider declaration of an interim dividend for the financial year 2025 to 2026 at the November 7, 2025 meeting (Key Developments) Record date for the proposed interim dividend to be fixed during the upcoming board meeting (Key Developments) Valuation Changes The discount rate has risen slightly from 13.34% to 13.35%, reflecting a marginally higher required return on equity.
ナラティブ更新 • Dec 07

506285: Interim Dividend Decision Will Drive Bullish Sentiment Into 2025

Narrative Update on Bayer CropScience Analysts have trimmed their price target for Bayer CropScience by approximately EUR 275, reflecting slightly softer expectations for revenue growth and profit margins, even as long term valuation multiples remain supportive. What's in the News A board meeting is scheduled for November 7, 2025 to review the unaudited financial results for the quarter ended September 30, 2025.
ナラティブ更新 • Nov 23

506285: Interim Dividend Consideration Will Drive Bullish Momentum Into 2025

Narrative Update on Bayer CropScience Analysts have lowered their fair value estimate for Bayer CropScience from €5,939 to €5,556. They attribute this reduction to a slightly lower projected profit margin, which outweighs improvements in expected revenue growth and a modest decrease in the discount rate.
User avatar
新しいナラティブ • May 18

Seeds, Traits And Biofuels Will Unlock New Value Pools

Strategic cost reductions and efficiency improvements are expected to enhance net margins and unlock substantial additional cash.

株主還元

506285IN ChemicalsIN 市場
7D-3.4%4.9%2.1%
1Y-0.2%4.3%8.1%

業界別リターン: 506285過去 1 年間で4.3 % の収益を上げたIndian Chemicals業界を下回りました。

リターン対市場: 506285は、過去 1 年間で8.1 % のリターンを上げたIndian市場を下回りました。

価格変動

Is 506285's price volatile compared to industry and market?
506285 volatility
506285 Average Weekly Movement4.0%
Chemicals Industry Average Movement7.1%
Market Average Movement7.1%
10% most volatile stocks in IN Market10.2%
10% least volatile stocks in IN Market4.7%

安定した株価: 506285 、 Indian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。

時間の経過による変動: 506285の 週次ボラティリティ ( 4% ) は過去 1 年間安定しています。

会社概要

設立従業員CEO（最高経営責任者ウェブサイト
18961,169Simon-Thorsten Wiebuschwww.bayer.in

バイエル クロップサイエンス社は、殺虫剤、殺菌剤、除草剤、その他さまざまな農薬製品、トウモロコシ種子の製造、販売、流通をインド、ドイツ、バングラデシュ、および海外で行っている。主に循環器科、婦人科、糖尿病科、腫瘍科、眼科の治療分野における医薬品、コンピューター断層撮影装置、X線装置、磁気共鳴画像装置を提供している。また、軽度の疾病を治療するための日常的な健康ソリューションとして使用される消費者向け健康製品を提供するほか、トウモロコシや水稲などのハイブリッド種子の販売・流通も行っている。さらに、FarmRiseや散布サービス用ドローンなどのデジタル・アプリケーションで構成されるデジタル農業製品を提供するほか、リモートセンシング、IoTセンサー、GPS、人工知能、データ分析などの各種技術を提供し、作物の生育、土壌の品質、天候パターンなどを監視・管理している。また、製品の輸出も行っている。バイエル クロップサイエンス社は1863年に設立され、インドのテーンに本社を置いている。

Bayer CropScience Limited 基礎のまとめ

Bayer CropScience の収益と売上を時価総額と比較するとどうか。
506285 基礎統計学
時価総額₹207.13b
収益（TTM）₹6.70b
売上高(TTM)₹56.21b
30.9x
PER（株価収益率
3.7x
P/Sレシオ

506285 は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
506285 損益計算書（TTM）
収益₹56.21b
売上原価₹34.00b
売上総利益₹22.21b
その他の費用₹15.50b
収益₹6.70b

直近の収益報告

Dec 31, 2025

次回決算日

該当なし

一株当たり利益（EPS）149.17
グロス・マージン39.51%
純利益率11.93%
有利子負債／自己資本比率3.3%

506285 の長期的なパフォーマンスは？

過去の実績と比較を見る

配当金

2.7%
現在の配当利回り
84%
配当性向

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/09 09:01
終値2026/05/08 00:00
収益2025/12/31
年間収益2025/03/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Bayer CropScience Limited 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。26

アナリスト機関
null null360 ONE Capital Market Private Limited
null nullAnand Rathi Shares and Stock Brokers Limited
Himanshu BinaniAnand Rathi Shares and Stock Brokers Limited